Linsitinib
Oral therapy candidate for thyroid eye disease
Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.
About
Linsitinib is Sling Therapeutics' lead pipeline program in development as a late-stage oral therapy for thyroid eye disease (TED).
- Website
- slingtx.com
- Added via
- web
- Ownership
- unclaimed
Where to go
Product details
- Product kind
- Other